# Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients

> **NCT01129336** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 44 (actual)

## Conditions studied

- First or Second Line HER2-negative Breast Cancer
- Metastatic Disease Without Bone Metastasis

## Interventions

- **DRUG:** Zoledronic acid
- **DRUG:** Standard Therapy

## Key facts

- **NCT ID:** NCT01129336
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2014-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01129336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01129336, "Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01129336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*